We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Viral Protein Combats the "Same" Human and Monkey Defences Differently

Viral Protein Combats the "Same" Human and Monkey Defences Differently

Viral Protein Combats the "Same" Human and Monkey Defences Differently

Viral Protein Combats the "Same" Human and Monkey Defences Differently

Vpu protein from a simian immunodeficiency virus (SIV) isolated from a wild monkey in Africa can antagonize a human restriction factor, BST2 protein. Credit: Department of Molecular Virology, TMDU
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Viral Protein Combats the "Same" Human and Monkey Defences Differently"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In the epic battle between hosts and viruses, viruses are constantly evolving to be more infectious. Now, researchers from Japan have found that human genes also evolve to help protect our bodies from invasion by life-threatening viruses.

In a study published in December in Journal of Virology, researchers from Tokyo Medical and Dental University (TMDU) have revealed that a monkey variant of human immunodeficiency virus (HIV) can counteract a human protein that defends against viral infection in a different way than it counteracts the same protein in monkeys.

Simian immunodeficiency virus (SIV) is closely related to HIV, and both viruses tend to use similar strategies to escape their hosts’ defenses, which also tend to be very similar. One of these defenses is a protein called tetherin (also known as BST-2 or CD317). If a cell is invaded by the virus, tetherin prevents the virus from leaving the cell and infecting other nearby cells. To counter this measure, HIV and SIV make a protein called viral protein U (Vpu) that attaches to tetherin and blocks its effects.

“Because viruses adapt to their hosts, HIV Vpu is most effective against human tetherin, while SIV Vpu is most effective against monkey tetherin,” explains Dr. Takeshi Yoshida, senior author of the study. “But in at least one unusual case, a strain of SIV that typically infects the greater spot-nosed monkey can also overcome human defenses, which suggests that SIV potentially infects humans.”

To explore how SIV Vpu affects human tetherin, the researchers mutated different parts of the protein and looked at how well it blocked tetherin’s normal activities and effects.

“The results were unexpected,” says Dr. Weitong Yao, lead author. “We discovered that the parts of SIV Vpu that are needed to counteract monkey tetherin  are not the same as the parts needed to counteract human tetherin.”

The researchers pinpointed seven specific amino acids (the basic building blocks of proteins) that are needed for SIV to block human tetherin. Importantly, these seven amino acids were not essential for the virus to block monkey tetherin.

“What this tells us is that SIV Vpu may use a totally distinct mechanisms to counteract the effects of monkey and human tetherin,” says Yoshida.

Given the different approaches that this viral protein uses to neutralize monkey and human tetherin, it seems likely that the gene encoding human tetherin faced different pressures over the course of evolution than the gene encoding monkey tetherin. The results from this study could help us better understand the evolution of host genes as a result of host-pathogen interactions.

Reference: Yao W, Strebel K, Yamaoka S, Yoshida T. Simian immunodeficiency virus SIVgsn-99CM71 Vpu employs different amino acids to antagonize human and greater spot-nosed monkey BST-2. J. Virol. 2022;96(4):e01527-21. doi: 10.1128/JVI.01527-21


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.